Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk files annual report with the SEC
Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk A/S Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
WRAL5d
Weight loss pill could replace injections, would be transformative for millions
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...
Taiwan News6d
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the ...
Nasdaq5d
Novo Nordisk files annual report with the SEC
The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com. Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of ...